Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TAF1 | P21675 | 1/20 | 0.39 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24485322 | 1.00 | ACHE (0.48) | ACHELMNAHTTGAAPOLB | |
| SCHEMBL29095832 | 0.84 | ACHE (0.45) | ACHELMNAHTTGAAPOLB | |
| SCHEMBL30664471 | 0.81 | MAOB (0.49) | ACHELMNAHTTGAAALDH1A1 | |
| SCHEMBL29712980 | 0.81 | KMT2A (0.52) | LMNAHTTALDH1A1KDM4ETSHR | |
| SCHEMBL24470634 | 0.81 | KMT2A (0.52) | LMNAHTTALDH1A1KDM4ETSHR | |
| SCHEMBL24470827 | 0.81 | CASP3 (0.62) | ACHELMNAHTTALDH1A1KDM4E | |
| SCHEMBL32664128 | 0.80 | PKM (0.52) | LMNAHTTGAAPOLBALDH1A1 | |
| SCHEMBL24470614 | 0.80 | USP30 (0.50) | GAAPOLB | |
| SCHEMBL29095744 | 0.80 | USP30 (0.50) | GAAPOLB | |
| SCHEMBL24470661 | 0.80 | KMT2A (0.51) | LMNAHTTGAAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-28 | — | — | US | disclosed |
| WO-2022112352-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | ACHE 1578/4885LMNA 3056/4885HTT 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.